Program
BAT4406F
A development code. Also written as “BAT4406F Injection”.
Its studies are mostly in Nephrosis, Lipoid · Neuromyelitis Optica, led by Bio-Thera Solutions.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bio-Thera Solutions | 32 open or running | phase 3since Mar 24, 2026 | Sep 26, 2019 | Dec 31, 2027phase 2 · NCT06044350 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 26, 2019First study: phase 1 study in Neuromyelitis OpticaFirst studyNCT04146285 · 15 enrolled · China
- Jul 31, 2023Phase 2 study in Optic Neuromyelitis Spectrum DiseaseNCT06044350 · 162 enrolled · China
- Mar 24, 2026Phase 3 study in Nephrosis, LipoidPhase 3 reachedNCT07499700 · 192 planned · China
- Oct 2, 2026Primary completion moved from 2026-05-31 to 2027-12-31Date moved laterphase 2 · +19 months · NCT06044350
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Optic Neuromyelitis Spectrum DiseaseNCT06044350
- Oct 26, 2030Primary completion: phase 3 study in Nephrosis, LipoidNCT07499700
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07499700Nephrosis, Lipoid · China | 3 | Recruiting | Oct 26, 2030 | 192 |
| NCT06044350Optic Neuromyelitis Spectrum Disease · China | 2 | Active, not recruiting | Dec 31, 2027 | 162 |
| NCT04146285Neuromyelitis Optica · China | 1 | Completed | Mar 13, 2023 | 15 |
How it is read
Names in the registry
- “BAT4406F”, 2 entries
- “BAT4406F Injection”, 1 entry
Codes read as this program: BAT4406F.
Conditions, from the studies’ own filings
- Nephrosis, Lipoid, 1 study
- Neuromyelitis Optica, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.